Search Results

Your search for Douglas B. Johnson, MD, MSCI matches 2 pages

Showing 1 - 2

By The ASCO Post Staff / 2024 NCCN Annual Conference

Douglas B. Johnson, MD, MSCI, on Cutaneous Melanoma: Treatment Updates

Douglas B. Johnson, MD, MSCI, of Vanderbilt-Ingram Cancer Center, discusses updated guidelines on the use of neoadjuvant therapy, as well as first- and later-line systemic therapies to treat patients with cutaneous melanoma.

skin cancer

immunotherapy

By Matthew Stenger / Thursday, May 9, 2019 2:15 PM

PD-1 Inhibitor–Associated Cutaneous Toxicity and Clinical Outcomes in Advanced Melanoma

In a research letter published in JAMA Oncology, Quach et al found that cutaneous toxicities related to anti–programmed cell death protein 1 (PD-1) treatment—specifically, vitiligo and rash—were associated with improved clinical outcomes in advanced melanoma. Study Details The...

Apr

Today In Oncology

Search Results

Your search for Douglas B. Johnson, MD, MSCI matches 2 pages

Douglas B. Johnson, MD, MSCI, on Cutaneous Melanoma: Treatment Updates

PD-1 Inhibitor–Associated Cutaneous Toxicity and Clinical Outcomes in Advanced Melanoma

Malpractice Risk With Active Surveillance for Patients With Low-Risk Cancer

Atezolizumab/Cabozantinib vs Docetaxel in Previously Treated Metastatic NSCLC

An Exosome-Based Liquid Biopsy for Early Detection of Pancreatic Cancer

Accelerated Aging May Be a Risk Factor for Early-Onset Cancers in Younger Generations

Barriers to Autologous Hematopoietic Cell Transplantation in Multiple Myeloma